
Yahoo · 30 de oct de 2026
The latest installment in BioPharma Dive’s visualization-focused series looks at Wall Street’s response to a trio of closely watched presentations at a top meet…
MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
No hay suficientes datos históricos para mostrar el gráfico de MRNA.
Precio
$ 19.370
Var. %
+0,62%
Volumen operado
386.179
Precio MRNA
US$ 220,76
Teórico (precio / ratio)
MRNA ÷ 19
US$ 11,62
Sí, existe el CEDEAR de MRNA (Moderna Inc) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es MRNA.
El ticker del CEDEAR de Moderna Inc en Argentina es MRNA. La acción subyacente cotiza en NASDAQ con el símbolo MRNA.
El CEDEAR MRNA tiene un ratio de 19:1. Eso significa que 19 CEDEARs equivalen a 1 acción de MRNA.
El CEDEAR MRNA cotiza hoy a $ 19.370 en pesos argentinos, con una variación diaria de +0,62%.
Otros CEDEARs de Salud.

Yahoo · 30 de oct de 2026
The latest installment in BioPharma Dive’s visualization-focused series looks at Wall Street’s response to a trio of closely watched presentations at a top meet…

Yahoo · 30 de oct de 2026
Legal experts say that pharma outcome bets on platforms like Kalshi and Polymarket pose new insider trading risks.

Yahoo · 30 de oct de 2026
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key exp…
Cotización
US$ 12,29
vs teórico
+5,78%
Cotización MEP implícita
$ 1.576,08
Cotización
US$ 10,55
vs teórico
-9,2%
Cotización Cable implícita
$ 1.836,02
La acción subyacente MRNA (Moderna Inc) cotiza a US$ 220,76 en su mercado de origen (NASDAQ).
El precio teórico del CEDEAR MRNA se calcula dividiendo el precio de MRNA por el ratio (19). Hoy resulta en US$ 11,62.
En BYMA podés operar MRNA en pesos, MRNAD en dólar MEP y MRNAC en dólar cable. Cada modalidad refleja un tipo de cambio distinto.
En esta página encontrás un gráfico con el precio histórico del CEDEAR MRNA en pesos argentinos, con datos de data912.

Yahoo · 30 de oct de 2026
Merck & Co., Inc. (NYSE:MRK) reported third-quarter 2026 revenue of $18.1 billion, up 5% from a year earlier, as growth in oncology, vaccines, cardiometabolic p…

Yahoo · 29 de oct de 2026
These biotechs’ valuations are through the roof.

Yahoo · 29 de oct de 2026
GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.

Yahoo · 29 de oct de 2026
Merck's Q3 earnings and sales beat estimates as Keytruda and newer products drive growth, prompting the company to raise its 2026 earnings outlook.

Yahoo · 29 de oct de 2026
Dow Jones component Merck hiked its 2026 outlook Thursday on the back of a solid third-quarter report that included a notable Keytruda beat.
Noticias vía Finnhub